HeartBeam Inc. Honored with 2025 Innovation Award for Pioneering Remote Cardiac Diagnostics

HeartBeam Inc. (NASDAQ: BEAT), a leader in medical technology focused on revolutionizing cardiac care, has been recognized with the 2025 Innovation Award in Remote Cardiac Diagnostics by the Medical Device Network Excellence Awards. This accolade highlights the company's FDA-cleared 3D ECG technology, a breakthrough that facilitates clinical-grade arrhythmia diagnostics outside traditional medical settings through a compact, cable-free device. The technology's synthesized 12-lead ECG software is currently undergoing FDA review, with plans for commercialization following clearance. This recognition underscores HeartBeam's commitment to advancing remote cardiac care and its potential to transform patient outcomes by enabling timely and accurate heart health monitoring anywhere.

The award not only celebrates HeartBeam's innovative approach to cardiac diagnostics but also reinforces the importance of accessible, high-quality healthcare solutions. With 13 U.S. and 4 international patents, HeartBeam is at the forefront of developing portable devices that empower physicians to detect and manage cardiac conditions effectively, regardless of the patient's location. For more details on HeartBeam's achievements and technology, visit https://ibn.fm/vEL8J.